NPW1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Improving Cash GenerationMaterial FCF improvement over 2024–2025 indicates stronger internal funding for R&D, capital investment, dividends and buybacks. Sustained cash generation enhances strategic flexibility, supports deleveraging and funds the multi-year RISE targets without reliance on external financing.
Re-accelerating, Broad-based Revenue GrowthConsistent mid-single-digit organic growth across Orthopaedics, Sports Medicine & ENT and Advanced Wound Management shows diversified end-market demand. Multi-segment breadth reduces single-product cyclicality and supports durable revenue compounding aligned with stated 6–7% organic CAGR targets.
Innovation-led Product Adoption (CORI & New Launches)Strong adoption of new devices and robotics (CORI) and a high share of growth from recent launches indicate a sustainable competitive moat. Installed capital and consumable pull-through create recurring procedure-driven revenue and support higher long-term unit economics.
Bears Say
China VBP Procurement PressureStructural procurement policy (VBP) in China compresses pricing and margins in that market. Even with limited sales share, persistent VBP-driven pricing pressure creates recurring profit headwinds and increases execution risk for market recovery and margin normalization.
U.S. Reimbursement Change For Skin SubstitutesRegulatory reimbursement shifts are structural and reduce addressable revenue and margins for the skin-substitutes portfolio. This forces product mix, channel and pricing adjustments and could lower long-term unit economics in AWM unless offset by new product positioning or alternate care settings.
Near-term Acquisition Dilution & Integration CostsPlanned M&A is strategically aimed at long-term growth but creates near-term dilution and integration burdens. Short-term profit and ROIC pressure plus ongoing restructuring and site moves raise execution risk and can delay expected accretion and cash returns until integration is complete.
NPW1 FAQ
What was Smith & Nephew plc’s price range in the past 12 months?
Currently, no data Available
What is Smith & Nephew plc’s market cap?
Smith & Nephew plc’s market cap is CHF10.60B.
When is Smith & Nephew plc’s upcoming earnings report date?
Smith & Nephew plc’s upcoming earnings report date is Aug 04, 2026 which is tomorrow.
How were Smith & Nephew plc’s earnings last quarter?
Smith & Nephew plc released its earnings results on Mar 02, 2026. The company reported CHF0.481 earnings per share for the quarter, beating the consensus estimate of CHF0.471 by CHF0.01.
Is Smith & Nephew plc overvalued?
According to Wall Street analysts Smith & Nephew plc’s price is currently Undervalued.
Does Smith & Nephew plc pay dividends?
Smith & Nephew plc does not currently pay dividends.
What is Smith & Nephew plc’s EPS estimate?
Smith & Nephew plc’s EPS estimate is 0.38.
How many shares outstanding does Smith & Nephew plc have?
Smith & Nephew plc has 839,857,200 shares outstanding.
What happened to Smith & Nephew plc’s price movement after its last earnings report?
Smith & Nephew plc reported an EPS of CHF0.481 in its last earnings report, beating expectations of CHF0.471. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Smith & Nephew plc?
Currently, no hedge funds are holding shares in CH:NPW1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Smith & Nephew Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF15.36 (― Upside)
CHF15.36 (― Upside)
Insider Transactions
Sold Shares
Worth £53.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.41%
12-Months-Change
Fundamentals
Return on Equity
2.29%
Trailing 12-Months
Asset Growth
-5.96%
Trailing 12-Months
Company Description
Smith & Nephew plc
Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstruction. This segment also provides trauma and extremities products, including internal and external fixation devices crucial for stabilizing severe fractures and correcting deformities. In the sports medicine field, the company furnishes surgeons with comprehensive joint repair solutions. These encompass specialized instruments, advanced technologies, and implants necessary for minimally invasive joint surgeries, addressing soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, its arthroscopic enabling technologies support surgical visualization and intervention inside joints, comprising fluid management equipment, high-definition cameras, digital image capture systems, scopes, light sources, and monitors. It also supplies radiofrequency, electromechanical, and mechanical tissue resection devices, along with hand instruments for removing damaged tissue, and provides ear, nose, and throat (ENT) solutions. Furthermore, Smith & Nephew delivers sophisticated advanced wound management solutions. This category features products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its offerings extend to advanced wound bioactives, incorporating biologics and other active technologies for debridement, dermal repair, and regeneration, as well as regenerative medicine products like skin, bone graft, and articular cartilage substitutes. The advanced wound devices portfolio includes traditional and single-use negative pressure wound therapy systems, alongside hydrosurgery devices. Primarily serving healthcare providers, Smith & Nephew plc was founded in 1856 and maintains its corporate headquarters in Watford, United Kingdom.
NPW1 Stock 12 Month Forecast
Average Price Target
―Advanced Medical Solutions
―
ConvaTec
―
Hikma Pharmaceuticals
―
PureTech Health
―
Spire Healthcare
―








